Literature DB >> 861132

Phenytoin concentrations in mixed, parotid and submandibular saliva and serum measured by radioimmunoassay.

J W Paxton, B Whiting, K W Stephen.   

Abstract

1 Concentrations of phenytoin in mixed, parotid and submandibular saliva and serum were determined in normal subjects after an oral dose, using a specific double antibody radioimmunoassay which requires only 20 micronl fluid. 2 Semi-log concentration-time plots of phenytoin concentration in mixed saliva and serum gave good parallelism after the initial 14 h post-administration period. 3 The mean ratio of the mixed saliva: serum phenytoin concentration was 10.3% +/- 1.5 (s.d.) in seven normal subjects. 4 Phenytoin concentrations found in separate parotid and submandibular salivary fractions did not differ but were significantly greater (P less than 0.001) than those found in mixed saliva. 5 Phenytoin concentrations in all salivary fractions were independent of the volume of fluid produced and the degree of stimulation. 6 The rate of phenytoin secretion in the parotid and submandibular fluid was proportional to the salivary flow rate. 7 These data suggest that mixed saliva may be a suitable medium for the monitoring of phenytoin concentrations and may provide a non-invasive alternative to the direct determination of phenytoin in serum.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 861132      PMCID: PMC1429005          DOI: 10.1111/j.1365-2125.1977.tb00692.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  6 in total

1.  Parotid fluid flow rate as related to whole saliva volume.

Authors:  I L SHANNON
Journal:  Arch Oral Biol       Date:  1962 May-Jun       Impact factor: 2.633

2.  Methods for collecting individual components of mixed saliva: the relevance to clinical pharmacology.

Authors:  K W Stephen; C F Speirs
Journal:  Br J Clin Pharmacol       Date:  1976-04       Impact factor: 4.335

3.  Phenytoin and phenobarbital concentrations in saliva and plasma measured by radioimmunoassay.

Authors:  C E Cook; E Amerson; W K Poole; P Lesser; L O'Tuama
Journal:  Clin Pharmacol Ther       Date:  1975-12       Impact factor: 6.875

4.  Production and characterisation of antisera to diphenylhydantoin suitable for radioimmunoassay.

Authors:  J W Paxton; F J Rowell; J G Ratcliffe
Journal:  J Immunol Methods       Date:  1976       Impact factor: 2.303

5.  Salivary phenytoin radioimmunoassay. A simple method of the assessment of non-protein bound drug concentrations.

Authors:  J W Paxton; F Rowell; J G Ratcliffe; D G Lambie; R Nanda; I D Melville; R H Johnson
Journal:  Eur J Clin Pharmacol       Date:  1977       Impact factor: 2.953

6.  Salivary phenytoin concentrations in epilepsy and in chronic renal failure.

Authors:  F Reynolds; P N Ziroyanis; N F Jones; S E Smith
Journal:  Lancet       Date:  1976-08-21       Impact factor: 79.321

  6 in total
  13 in total

Review 1.  Therapeutic drug monitoring in saliva. An update.

Authors:  R K Drobitch; C K Svensson
Journal:  Clin Pharmacokinet       Date:  1992-11       Impact factor: 6.447

Review 2.  Therapeutic drug monitoring of phenytoin. Rationale and current status.

Authors:  M Levine; T Chang
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

3.  The effect of pirenzepine on gastric emptying and salivary flow rate: constraints on the use of saliva paracetamol concentrations for the determination of paracetamol pharmacokinetics.

Authors:  F Kamali; C Edwards; M D Rawlins
Journal:  Br J Clin Pharmacol       Date:  1992-03       Impact factor: 4.335

Review 4.  Therapeutic drug monitoring in saliva.

Authors:  M Danhof; D D Breimer
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

Review 5.  Oral absorption and secretion of drugs.

Authors:  C F Speirs
Journal:  Br J Clin Pharmacol       Date:  1977-04       Impact factor: 4.335

6.  A descriptive systematic review of salivary therapeutic drug monitoring in neonates and infants.

Authors:  Laura Hutchinson; Marlene Sinclair; Bernadette Reid; Kathryn Burnett; Bridgeen Callan
Journal:  Br J Clin Pharmacol       Date:  2018-03-25       Impact factor: 4.335

7.  Effect of saliva flow rate on saliva phenytoin concentrations: implications for therapeutic monitoring.

Authors:  F Kamali; S H Thomas
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 8.  Therapeutic drug monitoring of antiarrhythmic agents.

Authors:  J E Brown; D G Shand
Journal:  Clin Pharmacokinet       Date:  1982 Mar-Apr       Impact factor: 6.447

Review 9.  Drug level monitoring in paediatric practice.

Authors:  G W Rylance; T A Moreland
Journal:  Arch Dis Child       Date:  1980-02       Impact factor: 3.791

10.  Salivary salicylate secretion and flow rate.

Authors:  M S Roberts; R H Rumble; P M Brooks
Journal:  Br J Clin Pharmacol       Date:  1978-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.